$0.74
7.34% yesterday
Nasdaq, Jun 27, 10:13 pm CET
ISIN
US15117N5032
Symbol
IMNN

Celsion Corporation Stock price

$0.74
-1.53 67.40% 1M
-0.05 6.68% 6M
-0.21 22.11% YTD
-0.39 34.51% 1Y
-1.18 61.46% 3Y
-55.21 98.68% 5Y
-492.76 99.85% 10Y
-5,244.01 99.99% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.06 7.34%
ISIN
US15117N5032
Symbol
IMNN
Sector

Key metrics

Basic
Market capitalization
$15.0m
Enterprise Value
$12.2m
Net debt
$-2.9m
Cash
$2.9m
Shares outstanding
14.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
23.95
Financial Health
Equity Ratio
43.68%
Return on Equity
-447.66%
ROCE
-1,722.92%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.0m | -
EBIT
$-18.3m
Net Income
$-17.8m | $-16.5m
Free Cash Flow
$-16.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
10.83% | -
EBIT
10.26%
Net Income
5.57% | 13.26%
Free Cash Flow
24.01%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.22
FCF per Share
$-1.10
Short interest
19.72%
Employees
25.00
Rev per Employee
$0.00
Show more

Is Celsion Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Celsion Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Celsion Corporation forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Celsion Corporation forecast:

Buy
90%
Hold
10%

Financial data from Celsion Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.75 7.75
8% 8%
-
- Research and Development Expense 11 11
12% 12%
-
-18 -18
11% 11%
-
- Depreciation and Amortization 0.24 0.24
85% 85%
-
EBIT (Operating Income) EBIT -18 -18
10% 10%
-
Net Profit -18 -18
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Celsion Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celsion Corporation Stock News

Neutral
GlobeNewsWire
10 days ago
ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO
Neutral
GlobeNewsWire
11 days ago
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines
Neutral
GlobeNewsWire
25 days ago
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response
More Celsion Corporation News

Company Profile

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Head office United States
CEO Stacy Lindborg
Employees 25
Founded 1982
Website imunon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today